Patent application number | Description | Published |
20080213890 | Antibody-avidin fusion proteins as cytotoxic drugs - Methods and compositions for inducing apoptosis and/or inhibiting proliferation of cells. The method includes exposing the cells to a cytotoxic agent which is made up of a targeting moiety and an avidin moiety wherein the targeting moiety is capable of binding to one or more receptors located on the cells. The invention is based on the discovery that attaching an avidin moiety to non-toxic targeting moieties produces a cytotoxic agent which can be used to treat tumor cells both in vivo and in vitro. The present cytotoxic agent eliminates the use of biotinylated toxic drugs which previously have been conjugated to antibody-avidin targeting vehicles. | 09-04-2008 |
20110091466 | IgE ANTIBODIES FOR THE TREATMENT OF CANCER - The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA). | 04-21-2011 |
20120321589 | Antibody Fusion Proteins with Disrupted Heparin-Binding Activity - Disclosed herein are polypeptides which comprise all or part of an antibody linked to all or part of a cytokine. The cytokine sequences of the polypeptides have a modified heparin binding region which disrupts, inhibits, or reduces the ability of the cytokine to bind a heparin compound as compared to a corresponding cytokine having an unmodified heparin binding region. Also disclosed are methods of treating cancer, inducing cell proliferation, and reducing the non-specific binding and/or non-specific localization of the polypeptides. | 12-20-2012 |
20130022614 | IgE ANTIBODIES FOR THE TREATMENT OF CANCER - The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA). | 01-24-2013 |
20130028891 | Unconjugated Anti-TfR Antibodies and Compositions Thereof for the Treatment of Cancer - Disclosed herein are methods and compositions for treating cancer. In particular, the in vivo efficacy of unconjugated anti-TfR antibodies, such as ch128.1, are disclosed herein. | 01-31-2013 |